A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Inclusion Criteria:

- Have moderate to severe Hidradenitis Suppurativa (HS) for at least 1 year (365 days)
prior to the baseline visit as determined by the investigator through participant
interview and/or review of the medical history

- Have HS lesions present in at least 2 distinct anatomic areas (examples include but
are not limited to left and right axilla; or left axilla and left inguinocrural fold)

- Had an inadequate response to an adequate course of appropriate oral antibiotics for
treatment of HS (or demonstrated intolerance to, or had a contraindication to oral
antibiotics for treatment of their HS) in the investigator's opinion

- Have a total abscess and inflammatory nodule (AN) count of greater than or equal to
(>=) 3 at the screening and baseline visit

- Must agree to daily use (throughout the entirety of the study) of one of the following
over-the-counter treatments to the body areas affected with HS lesions: either soap
and water, or a topical antiseptic wash containing chlorhexidine gluconate, triclosan,
or benzoyl peroxide, or a dilute bleach bath

Exclusion Criteria:

- Any other active skin disease or condition (example, bacterial, fungal or viral
infection) that could have interfered with assessment of HS

- Has a draining fistula count of greater than (>) 20 at the baseline visit

- Receipt of prescription topical therapies for the treatment of HS within 14 days prior
to the baseline visit

- Receipt of systemic non-biologic therapies for the treatment of HS less than (<) 4
Weeks prior to the baseline visit

- Receipt of any oral antibiotic treatment for HS or inflammatory disorders within 4
Weeks prior to the baseline visit